Performance monitoring is fundamental to track cloud application health and service-level agreement compliance, but with the emergence of multi-cloud deployments, it may become increasingly important also to create a feedback loop between runtime operation in multi-clouds and design-time reasoning. This is because the developer needs to acquire more information on the specific performance features of a cloud platform to better leverage its specificities.To support this goal, we have developed a set of open source components that extract quality-of-service (QoS) data from a target Java application using JMX, aggregate it in a time-series database, and finally deliver it in a prototype Java dashboard that may be integrated in a development environment, such as Eclipse, to display either live or historical QoS data. The architecture is not only limited to collection, aggregation, and display of QoS data, but it also allows the evaluation of hierarchical queries expressed using the Performance Trees graphical language. It is our intention that this will provide a cloud-independent uniform interface for developers to specify monitoring queries. Initial evaluation suggests that Cube on MongoDB provides appropriate scalability for this application.

No abstract

Background Anti-tumour necrosis factor antagonists (infliximab) as well as other molecules with different modes of action, including anti-integrin agents (vedolizumab), are currently used in patients with ulcerative colitis (UC Numerous studies have demonstrated a positive correlation between serum biologic drug concentrations and favourable therapeutic outcomes, whereas low or undetectable drug concentrations can lead to treatment failure. However, despite immunological issues, lack of and or loss of response may also be attributed to drug pharmacokinetics, of which penetration to the target tissue (colon wall) may play a crucial role Methods We used MRI to perform biochemical analyses of infliximab, adalimumab and vedolizumab concentrations testing the hypothesis that MRI relaxation time can be used to track antibodies in both mucosal biopsy samples and serum. All MR scans were performed with an Optima MR360 from General Electric Healthcare. To determine spin–lattice (T1) and spin–spin (T2) relaxation times, the Fast Spin Echo (FSE) sequence was used. Results The measured values of T1 relaxation times for infliximab, adalimumab, and vedolizumab were 2227 ± 35 ms, 2000 ± 22 ms and 1288 ± 15 ms, respectively. The obtained T2 relaxation times were 130 ± 11 ms, 90 ± 5, and 75 ± 10 ms, respectively. A decrease of both T1 and T2 values of 15 ± 3% are observed in serum from patients with ulcerative colitis. The values of infliximab and adalimumab were similar; the values of vedolizumab measurements in serum were about 50% lower. We find primary evidence that in T1 and T2 decreased in serum samples with ulcerative colitis and increase with the administration of infliximab, adalimumab and vedolizumab drugs. Samples of healthy tissue have T1 and T2 in the range of 2700 ± 5 ms and 150 ms ± 5 ms, respectively. A 30% decrease in T1 and T2 are observed for samples with ulcerative colitis. In this pilot study, we observed that values of T1 and T2 for tissues and serum that contain infliximab and adalimumab are similar, but vedolizumab shows a difference of about 30% when compared with infliximab and adalimumab. Conclusion MRI is an excellent method for quantitative and qualitative measurements of drug content in tissues and biological fluids. This is an innovative use of magnetic resonance imaging to develop a methodology for imaging of drugs that act as contrast agents via interaction with water in serum and tissue.

Introduction. Cytisine, Cytisinum (C11H14N2O), is an organic chemical compound. Cytisine is heterotricyclic compound that is the toxic principle in Laburnum seeds and is found in many members of the Fabaceae (legume, pea or bean) family. Aim. The aim of the study is to measure the influence of water on the form of drug in the magnetic field 1.5 Tesla. Material and methods. For this purpose, magnetic resonance imaging tests were performed to check the solubility of pure cytisine, Desmoxan tablets and Tabex capsules. Results. From a pharmacological point of view, both Desmoxan tablets and Tabex capsules should exert the same effect on the human body, this is due to the identical content of the active substance, in this case cytisine (1.5 mg). Conclusion. The differences in the results obtained may be related to additional excipients that contain medications, but it is believed that they should not have a negative impact on the action of the active substance.

No abstract